Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

SOUTH SAN FRANCISCO, Calif., December 19, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating ...

Leap Therapeutics (LPTX) lost 63% after announcing it will not run a Phase 3 trial for its lead asset sirexatamab in gastric ...

AbbVie ABBV announced that the FDA has granted a Breakthrough Therapy Designation (BTD) to its investigational antibody-drug conjugate (ADC) telisotuzumab vedotin ...

The FDA accepts Roche's (OTCQX:RHHBY) supplemental New Drug Application (sNDA) seeking approval for Alecensa (alectinib) for the first-line treatment of anaplastic ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Roche RHHBY-partnered Venclexta sales are likely ... Let us delve deeper to understand whether to buy, sell or hold the stock. Shares of AbbVie have risen nearly 8% in the past year against ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...